论文部分内容阅读
Gastrointestinal stromal tumor(GIST)is the most common sarcoma of the gastrointestinal tract.Oncogenic KIT or PDGFRA receptor tyrosine kinase mutations are compelling therapeutic targets in GISTs,and the KIT/PDGFRA kinase inhibitor,imatinib/sunitinib,is standard of care for patients with metastatic GIST